The molecular tumor board

被引:0
|
作者
Konukiewitz, Bjoern [1 ]
Kellers, Franziska [1 ]
Nettersheim, Alexander [1 ]
Pfarr, Nicole [2 ]
Kirfel, Jutta [3 ]
机构
[1] Univ klinikum Schleswig Holstein, Inst Pathol, Campus Kiel Arnold-Heller-Str 3, D-24105 Kiel, Germany
[2] Tech Univ Munich, TUM Sch Med & Hlth, Inst Pathol, Munich, Germany
[3] Univ klinikum Schleswig Holstein, Inst Pathol, Campus Lubeck, Lubeck, Germany
来源
ONKOLOGIE | 2024年 / 30卷 / 10期
关键词
Biomarker; Whole exome sequencing; Precision medicine; Targeted therapy; Molecular pathology; PATHOLOGY;
D O I
10.1007/s00761-024-01561-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Precision oncology is an integral part of patient care in the centers for personalized medicine of the German Network for Personalized Medicine at many university hospitals. The aim is to provide patients with advanced and rare tumor diseases, for whom classic guideline-conform treatment is no longer an option, access to molecular targeted therapy. To this end, a comprehensive molecular examination of the tumor tissue is carried out and a search is performed for genetic changes that can be targeted with medication. The molecular tumor board is the central body of precision oncology, in which experts from different disciplines discuss cases and recommend possible treatment options. The classic concept of tumor therapy is largely abandoned; the treatment recommendations are increasingly based on entity-agnostic approaches and off-label therapies that are strictly oriented towards the individual molecular profile of the tumor and for which a promising effect has been achieved in other tumor entities or case reports. Pathology plays a key role here, as the results of the molecular examinations are summarized in an integrative pathological-anatomical report and interpreted and evaluated in the context of the diagnosis.
引用
收藏
页码:916 / 921
页数:6
相关论文
共 50 条
  • [1] The molecular tumor board
    Missios, Pavlos
    Beha, Janina
    Bitzer, Michael
    Malek, Nisar P.
    CHIRURG, 2021, 92 (11): : 1011 - 1015
  • [2] The molecular tumor board
    Missios, Pavlos
    Beha, Janina
    Bitzer, Michael
    Malek, Nisar P.
    ONKOLOGE, 2020, 26 (08): : 679 - 684
  • [3] Implementation of a Molecular Tumor Board
    Tafe, L. J.
    Chamberlin, M. D.
    Miller, T. W.
    de Abreu, F. B.
    Lefferts, J. A.
    Liu, X.
    Pettus, J. R.
    Marotti, J. D.
    Memoli, V. A.
    Schned, A. R.
    Suriawinata, A. A.
    Tsongalis, G. J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 744 - 744
  • [4] Integration of proteomics in the molecular tumor board
    Thiery, Johanna
    Fahrner, Matthias
    PROTEOMICS, 2024, 24 (12-13)
  • [5] Molecular tumor board-editorial
    Taghizadeh, Hossein
    Gerger, Armin
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2024, 17 (03) : 154 - 155
  • [6] Molecular tumor board prostate cancer
    Seitz, A. K.
    Heck, M. M.
    Kamer, M. W.
    Gruellich, C.
    UROLOGE, 2019, 58 (07): : 752 - 759
  • [7] Molecular Tumor Board: Resistance to Checkpoint Inhibitors
    Sullivan, Ryan
    ONCOLOGIST, 2018, 23 : S3 - S3
  • [8] Molecular tumor board-urothelial cancer
    Hupe, M. C.
    Gakis, G.
    Seiler, R.
    UROLOGE, 2019, 58 (07): : 760 - 767
  • [9] Molecular Tumor Board in Uro-oncology
    Kuebler, H.
    Merseburger, A. S.
    UROLOGE, 2019, 58 (07): : 745 - 746
  • [10] Das Molekulare TumorboardThe molecular tumor board
    Björn Konukiewitz
    Franziska Kellers
    Alexander Nettersheim
    Nicole Pfarr
    Jutta Kirfel
    Die Onkologie, 2024, 30 (10) : 916 - 921